<DOC>
	<DOCNO>NCT02870777</DOCNO>
	<brief_summary>Acute myeloid leukemia ( AML ) patient favorable intermediate cytogenetics diagnosis generally exclude first-line allo-SCT . However , patient may eventually relapse case . The purpose study establish risk stratification base cytogenetics minimal-residual-disease ( MRD ) analysis determine whether MRD-directed therapy low intermediate AML patient positive result term overall survival .</brief_summary>
	<brief_title>MRD-directed Therapy Low-risk Intermediate-risk AML .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<criteria>Lowrisk intermediaterisk AML Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study . Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MRD</keyword>
	<keyword>Acute myeloid leukemia</keyword>
</DOC>